Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review

Pharmaceutics

Umberto Tarantino¹  Caterina Claudia Lepre²  Maria Consiglia Trotta²  Michele D’Amico²  Alfredo Schiavone Panni³  Roberta Miranda³  Marco Paoletta³  Annalisa De Cicco³  Giuseppe Toro³  Annalisa Itro⁴ 

[1] Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy;Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy;Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy;PhD Course in Translational Medicine (XXXV Cycle), Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy;

关键词: tendinopathies;    tendons repair;    adipose-derived mesenchymal stem cells;    humans;   

DOI  :  10.3390/pharmaceutics14061151

来源: DOAJ

【 摘 要 】

The aim of the present systematic review was to provide a clear overview of the clinical current research progress in the use of adipose-derived mesenchymal stem cells (ASCs) as an effective therapeutic option for the management of tendinopathies, pathologies clinically characterized by persistent mechanical pain and structural alteration of the tendons. The review was carried out using three databases (Scopus, ISI Web of Science and PubMed) and analyzed records from 2013 to 2021. Only English-language papers describing the isolation and manipulation of adipose tissue as source of ASCs and presenting ASCs as treatment for clinical tendinopathies were included. Overall, seven clinical studies met the inclusion criteria and met the minimum quality inclusion threshold. Data extraction and quality assessment were performed by groups of three reviewers. The available evidence showed the efficacy and safety of ASCs treatment for tendinopathies, although it lacked a clear description of the biomolecular mechanisms underlying the beneficial properties of ASCs.

【 授权许可】

Unknown